Bausch Health Cos Inc. (NYSE:BHC) Receives $8.33 Consensus Target Price from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has received a consensus rating of “Reduce” from the five brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.3333.

A number of equities analysts have issued reports on BHC shares. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Weiss Ratings lowered Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research report on Thursday, February 19th. Truist Financial lifted their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Finally, Barclays dropped their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, February 25th.

Institutional Trading of Bausch Health Cos

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new position in Bausch Health Cos during the 1st quarter worth approximately $68,000. Jones Financial Companies Lllp increased its stake in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after purchasing an additional 23,451 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after purchasing an additional 9,834 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Bausch Health Cos during the second quarter worth $165,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC opened at $5.39 on Monday. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 1-year low of $4.25 and a 1-year high of $8.69. The stock has a market capitalization of $2.00 billion, a P/E ratio of 12.83 and a beta of 0.37. The business has a 50-day moving average price of $6.38 and a two-hundred day moving average price of $6.60.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.13). The business had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. Equities analysts predict that Bausch Health Cos will post 4.41 earnings per share for the current year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.